Mod GRF 1-29

Overview

Mod GRF 1-29, also widely known as CJC-1295 without DAC (Drug Affinity Complex), is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). It features four amino acid substitutions at positions 2, 8, 15, and 27 designed to increase resistance to enzymatic degradation while preserving full agonist activity at the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells.

The compound originates from research demonstrating that the biological activity of the 44-amino-acid native GHRH resides entirely within the first 29 residues (GHRH(1-29)), with the remaining 15 C-terminal amino acids contributing to metabolic stability but not receptor binding or activation. The truncated GHRH(1-29) fragment (known as sermorelin, marketed as Geref) was the first GHRH analog approved by the FDA but had limited clinical utility due to its very short half-life (approximately 10-20 minutes).

Mod GRF 1-29 addresses sermorelin's metabolic instability through four specific amino acid substitutions that protect known cleavage sites. The result is a compound with substantially improved half-life while maintaining the pulsatile GH release pattern characteristic of GHRH stimulation — a key distinction from exogenous growth hormone administration.

Important nomenclature clarification: Mod GRF 1-29 is frequently confused with CJC-1295 with DAC (Drug Affinity Complex). CJC-1295 with DAC is a different compound that includes a maleimidopropionic acid-modified lysine linker enabling covalent binding to serum albumin, resulting in a half-life of 6-8 days and sustained, non-pulsatile GH elevation. Mod GRF 1-29 (CJC-1295 without DAC) lacks this albumin-binding modification and produces shorter-duration, more pulsatile GH release. The two compounds have meaningfully different pharmacological profiles despite sharing the same four amino acid substitutions.

Structure and Sequence

Mod GRF 1-29 is based on the GHRH(1-29)-NH₂ backbone with four substitutions:

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Asn-Arg-NH₂

Four stabilizing substitutions:

Position	Native GHRH	Mod GRF 1-29	Rationale
2	Ala	D-Ala	Confers resistance to DPP-4 cleavage at the critical N-terminal dipeptide
8	Asn	Gln	Prevents deamidation (Asn to Asp conversion) that inactivates the molecule
15	Gly	Ala	Reduces susceptibility to trypsin-like cleavage
27	Met	Leu	Prevents oxidation of the methionine sulfur, which impairs receptor binding

• Molecular weight: approximately 3,367.9 g/mol
• C-terminal: Amidated (NH₂)

The D-alanine substitution at position 2 is the most critical modification, as DPP-4 cleavage of the N-terminal Tyr-Ala dipeptide is the primary inactivation pathway for native GHRH in circulation.

Mechanism of Action

GHRH Receptor Activation

Mod GRF 1-29 acts identically to native GHRH at the molecular level:

1. Receptor binding: Mod GRF 1-29 binds GHRHR on anterior pituitary somatotroph cells
2. Gs-coupled signaling: Activation of adenylyl cyclase, elevation of intracellular cAMP
3. PKA activation: Phosphorylation cascades leading to GH gene transcription and GH granule exocytosis
4. Pulsatile GH release: When administered as a bolus, produces a discrete GH pulse mimicking physiological secretion

Physiological GH Pulsatility

The pulsatile GH release pattern produced by Mod GRF 1-29 is considered more physiological than either continuous GH infusion (as would occur with CJC-1295 with DAC) or exogenous GH injection:

• Pulsatile GH stimulates liver IGF-1 production while allowing inter-pulse receptor resensitization
• Pulsatile patterns preserve the normal GH feedback loop (somatostatin negative feedback remains intact)
• Continuous GH elevation can lead to GH receptor desensitization and loss of GH-mediated signaling

Synergy with GH-Releasing Peptides (GHRPs)

Mod GRF 1-29 is most commonly discussed in the context of combination protocols with GH-releasing peptides (GHRPs) or growth hormone secretagogues (GHSs), which act through the ghrelin/GHS receptor (GHS-R1a). The rationale for combination is synergistic:

• GHRH (Mod GRF 1-29): "Amplifies" the GH pulse by increasing the amplitude of GH secretion from somatotrophs
• GHRPs (Ipamorelin, GHRP-2, GHRP-6, Hexarelin): "Initiate" the GH pulse by mimicking ghrelin signaling, suppressing somatostatin, and increasing the number of somatotrophs that participate in secretion

The combination of GHRH + GHRP can produce GH pulses 3-10 times larger than either compound alone, a synergy that has been confirmed in clinical studies using native GHRH combined with GHRP-6 or GHRP-2.

Somatostatin Interaction

GH release from Mod GRF 1-29 is modulated by hypothalamic somatostatin:

• During somatostatin troughs (natural pulsatility), Mod GRF 1-29 produces maximal GH release
• During somatostatin peaks, GH release is blunted regardless of GHRH stimulation
• This is why timing of administration (typically before sleep, when somatostatin is lower) and combination with GHRPs (which suppress somatostatin) are emphasized in research protocols

Research Summary

Area	Study/Context	Key Finding	Reference
GH stimulation	GHRH(1-29) dose-response	GHRH(1-29) produces dose-dependent GH release in healthy subjects; truncation retains full activity	Multiple, 1980s-1990s
GHRH + GHRP synergy	GHRH + GHRP-6 combination	Combination produced GH release 3-10x greater than either alone	Bowers et al., 1990; Veldhuis et al., 2001
Aging and GH decline	Somatopause studies	GHRH analogs partially restore youthful GH pulsatility in aging subjects	Corpas et al., 1992; Veldhuis et al., 2005
Body composition	GHRH analog in elderly	6 months of GHRH analog increased lean mass and reduced visceral fat in healthy elderly	Nass et al., 2008
Sleep-related GH	GH release during sleep	GHRH administration enhances slow-wave sleep-associated GH secretion	Steiger et al., 1992
DPP-4 resistance	In vitro stability	D-Ala2 substitution extends half-life >10-fold vs. native GHRH(1-29)	Frohman et al., 1989
Sermorelin (parent)	FDA-approved for GH deficiency diagnosis	Sermorelin (unmodified GHRH 1-29) was approved as Geref for diagnostic use and GH-deficient children	FDA approval, 1997

Pharmacokinetics

• Administration: Subcutaneous injection (standard); intravenous (research)
• Half-life: approximately 30 minutes (substantially longer than sermorelin's ~10-20 minutes, but much shorter than CJC-1295 with DAC's ~6-8 days)
• GH pulse onset: within 15-30 minutes of subcutaneous injection
• GH pulse duration: approximately 2-3 hours
• Peak GH levels: typically 30-60 minutes post-injection; amplitude depends on dose, timing, and combination with GHRPs
• Metabolism: Proteolytic degradation; the four substitutions protect the primary cleavage sites but do not render the molecule fully protease-resistant
• Typical research doses: 100-300 mcg per injection, 1-3 times daily
• Oral bioavailability: None (peptide is degraded in the GI tract)

Timing considerations:

• Pre-sleep administration capitalizes on natural somatostatin troughs and augments the physiological nocturnal GH surge
• Fasting state is preferred, as hyperglycemia and elevated free fatty acids blunt GH release
• Post-exercise administration may produce enhanced GH release due to exercise-induced somatostatin suppression

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Reconstitution

Parameter	Value
Vial size	5 mg
Bacteriostatic water	3.0 mL
Concentration	~1,667 mcg/mL
Storage (reconstituted)	2-8 °C, use within 1-2 weeks
Storage (lyophilized)	-20 °C

Dosing Schedule

Phase	Dose	Frequency	Duration
Starting	100-150 mcg	Once daily	Weeks 1-2
Mid-range	200 mcg	Once daily	Weeks 3-6
Target	250-300 mcg	Once daily	Weeks 7-12

Syringe Measurements (U-100 insulin syringe)

Dose	Units	Volume
100 mcg	6 units	0.06 mL
150 mcg	9 units	0.09 mL
200 mcg	12 units	0.12 mL
300 mcg	18 units	0.18 mL

Cycle Guidelines

• Cycle length: 8-12 weeks (up to 16 weeks)
• Route: Subcutaneous injection
• Timing: Bedtime preferred to align with natural nocturnal GH secretion; administer fasted
• Titration: Increase by ~50 mcg every 1-2 weeks
• Injection sites: Rotate between abdomen, thighs, and upper arms
• Note: Mod GRF 1-29 is functionally identical to CJC-1295 no DAC and follows the same dosing protocol

Common Discussion Topics

Mod GRF 1-29 vs. CJC-1295 with DAC

This is the most frequent source of confusion in the peptide community. The critical distinctions:

• Mod GRF 1-29 (no DAC): Short-acting, produces discrete GH pulses, mimics physiological pulsatility, requires multiple daily injections
• CJC-1295 with DAC: Long-acting (6-8 day half-life due to albumin binding), produces continuous GH elevation, loss of pulsatility, dosed 1-2 times per week
• Many researchers and clinicians prefer Mod GRF 1-29 because pulsatile GH release better preserves receptor sensitivity and downstream signaling fidelity

Combination Protocols with GHRPs

The standard research paradigm combines Mod GRF 1-29 with a GHRP such as Ipamorelin, GHRP-2, or GHRP-6. Each GHRP has a different profile:

• Ipamorelin: Most selective for GH release; minimal cortisol or prolactin elevation
• GHRP-2: Strong GH release; modest cortisol and prolactin effects; appetite stimulation
• GHRP-6: Strong GH release; notable appetite stimulation via ghrelin mimicry; cortisol elevation

Comparison to Tesamorelin

Tesamorelin is the only FDA-approved GHRH analog and is the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification. Compared to Mod GRF 1-29:

• Tesamorelin has established human safety and efficacy data (FDA-approved)
• Tesamorelin requires daily injection (similar to Mod GRF 1-29)
• Mod GRF 1-29 is shorter (29 vs. 44 amino acids), less expensive to synthesize, and potentially more accessible as a research compound
• Tesamorelin has published clinical trial data for visceral fat reduction and cognitive outcomes; Mod GRF 1-29's evidence base is primarily from studies using sermorelin or native GHRH

Age-Related GH Decline (Somatopause)

The decline in GH secretion with aging (somatopause) is driven in part by increased somatostatin tone and decreased GHRH signaling. GHRH analogs like Mod GRF 1-29 can partially restore youthful GH pulsatility, and this forms the theoretical basis for their interest in anti-aging research. However, whether restoring GH levels in aging adults produces net benefit (improved body composition, cognition, recovery) versus net risk (potential insulin resistance, theoretical cancer concerns) remains an open question.

Related Compounds

• Tesamorelin — The only FDA-approved GHRH analog, acting on the same receptor with established clinical data
• Semaglutide — A GLP-1 agonist relevant to metabolic discussions, particularly regarding body composition
• Tirzepatide — A dual incretin agonist, relevant in the broader context of metabolic optimization